Dipeptidyl peptidase-4 inhibitor decreases the risk of atrial fibrillation in patients with type 2 diabetes: a nationwide cohort study in Taiwan

BACKGROUND: Whether dipeptidyl peptidase-4 inhibitor (DPP4i) is associated with a lower risk of new-onset atrial fibrillation (AF) in patients with diabetes remains unclear. This study aimed to evaluate the risk of AF associated with use of DPP4i among a longitudinal cohort of patients with diabetes...

Descripción completa

Detalles Bibliográficos
Autores principales: Chang, Chia-Yu, Yeh, Yung-Hsin, Chan, Yi-Hsin, Liu, Jia-Rou, Chang, Shang-Hung, Lee, Hsin-Fu, Wu, Lung-Sheng, Yen, Kun-Chi, Kuo, Chi-Tai, See, Lai-Chu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5735601/
https://www.ncbi.nlm.nih.gov/pubmed/29258504
http://dx.doi.org/10.1186/s12933-017-0640-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5735601/
https://www.ncbi.nlm.nih.gov/pubmed/29258504
http://dx.doi.org/10.1186/s12933-017-0640-5

Ejemplares similares